Cardinal Health (NYSE:CAH) Issues FY 2027 Earnings Guidance

Cardinal Health (NYSE:CAH) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 12.400-12.600 for the period, compared to the consensus earnings per share estimate of 12.560. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several analysts recently issued reports on CAH shares. JPMorgan Chase & Co. increased their price target on shares of Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Weiss Ratings downgraded Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a research report on Wednesday, August 19th. Robert W. Baird lifted their target price on Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Evercore reissued an “outperform” rating and set a $270.00 target price on shares of Cardinal Health in a research note on Wednesday, August 12th. Finally, Royal Bank Of Canada started coverage on shares of Cardinal Health in a report on Wednesday, August 19th. They issued an “outperform” rating and a $276.00 target price for the company. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Cardinal Health presently has an average rating of “Moderate Buy” and an average target price of $266.56.

Cardinal Health Trading Up 3.5%

CAH stock opened at $230.25 on Friday. The firm has a market cap of $53.32 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 1.34 and a beta of 0.50. The stock has a 50-day moving average price of $233.01 and a 200-day moving average price of $220.03. Cardinal Health has a 1-year low of $150.77 and a 1-year high of $258.30.

Cardinal Health (NYSE:CAH) last released its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.08 earnings per share. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, analysts forecast that Cardinal Health will post 12.55 earnings per share for the current year.

Cardinal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a dividend of $0.5158 per share. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is 28.49%.

Insider Buying and Selling

In related news, insider Michelle Greene sold 11,650 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the transaction, the insider owned 10,330 shares in the company, valued at $2,434,987.60. The trade was a 53.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jason Hollar sold 44,529 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $236.18, for a total transaction of $10,516,859.22. Following the transaction, the chief executive officer directly owned 190,603 shares in the company, valued at approximately $45,016,616.54. This represents a 18.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 210,271 shares of company stock worth $49,626,657 over the last ninety days. 0.12% of the stock is owned by company insiders.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Cardinal Health entered into a binding letter of intent to extend its existing pharmaceutical distribution agreements with CVS Health through June 30, 2032. The agreement maintains the current scope of distribution services and reduces uncertainty around a major customer relationship. CVS Health was Cardinal Health’s only customer representing at least 10% of fiscal 2026 revenue or gross trade receivables, making the renewal particularly significant. Cardinal Health and CVS Health distribution agreement
• Positive Sentiment: Management reaffirmed fiscal 2027 adjusted earnings-per-share guidance of $12.40 to $12.60, broadly in line with the $12.56 analyst consensus, and maintained its long-term adjusted EPS growth target of 12% to 14%. The lack of a guidance reduction supports investor confidence in the company’s earnings trajectory. Cardinal Health outlook and stock reaction
• Positive Sentiment: Industry commentary identified Cardinal Health among medical and dental supply companies positioned to benefit from improving sector prospects, adding a supportive backdrop for the stock. Medical and dental supply stocks outlook

Cardinal Health Company Profile

Cardinal Health, Inc is a healthcare services and products company that supports pharmacies, hospitals, ambulatory surgery centers, physician offices and other healthcare providers. Its operations are primarily organized into Pharmaceutical and Medical segments.

The Pharmaceutical segment distributes branded, generic, specialty and over-the-counter medicines, as well as consumer health products. It also provides services related to specialty pharmaceuticals, pharmaceutical sourcing, nuclear and precision health products, and data and analytics for pharmaceutical manufacturers and healthcare organizations.

The Medical segment distributes medical and surgical products, including gloves, apparel, incontinence supplies, laboratory products and other essential items.